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Abstract
Background: Accurately determining renal function is essential for clinical management of HIV patients. Classically,
it has been evaluated by estimating glomerular filtration rate (eGFR) with the MDRD-equation, but today there is
evidence that the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation has greater diagnostic
accuracy. To date, however, little information exists on patients with HIV-infection. This study aimed to evaluate eGFR
by CKD-EPI vs. MDRD equations and to stratify renal function according to KDIGO guidelines.
Methods: Cross-sectional, single center study including adult patients with HIV-infection.
Results: Four thousand five hundred three patients with HIV-infection (864 women; 19%) were examined. Median age
was 45 years (IQR 37–52), and median baseline creatinine was 0.93 mg/dL (IQR 0.82–1.05). A similar distribution of
absolute measures of eGFR was found using both formulas (p= 0.548). Baseline median eGFR was 95.2 and 90.4 mL/min/
1.73 m2 for CKD-EPI and MDRD equations (p < 0.001), respectively. Of the 4503 measurements, 4109 (91.2%) agreed, with
a kappa index of 0.803. MDRD classified 7.3% of patients as “mild reduced GFR” who were classified as “normal function”
with CKD-EPI. Using CKD-EPI, it was possible to identify “normal function” (>90 mL/min/1.73 m2) in 73% patients and
“mild reduced GFR” (60–89 mL/min/1.73 m2) in 24.3% of the patients, formerly classified as >60 mL/min/1.73 m2 with
MDRD.
Conclusions: There was good correlation between CKD-EPI and MDRD. Estimating renal function using CKD-EPI equation
allowed better staging of renal function and should be considered the method of choice. CKD-EPI identified a significant
proportion of patients (24%) with mild reduced GFR (60–89 mL/min/1.73 m2).
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Background
Chronic kidney diseases (CKD) have become one of the
leading causes of mortality among patients with HIV in-
fection, and are often associated with comorbidities that
affect kidney function, such as diabetes mellitus and
hypertension [1–4]. The reported prevalence of renal
diseases ranges from 3 to 24% [4–8], depending on the
definition of renal disease, study population, and access
to health services. Furthermore, although the widespread
use of antiretroviral therapy (ARV) has decreased the
incidence of HIV-associated nephropathy, the overall
prevalence of renal disease continues to increase among
people living with HIV [9].
An accurate assessment of renal function in the HIV-
infected population is essential, because HIV treatment
with ARV involves complex drug regimens often accom-
panied by significant side effects and drug interactions.
A significant number of these drugs undergo renal elim-
ination and demand dose-adjustments according to
kidney function [10].
Methods based on the clearance of exogenous markers,
like inulin, 51Cr-EDTA and iohexol, are the gold standard
for glomerular filtration rate (GFR) measurement, but are
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cumbersome and infrequently used in clinical settings
[11]. Numerous equations used to estimate creatinine
clearance or GFR have been used over the past few
decades. Two of the most commonly used equations
(Cockroft-Gault [CG] and Modification of Diet in Renal
Disease [MDRD]) are derived from persons with GFR
≤90 mL/min/1.73 m2, have not been validated among per-
sons with normal kidney function, and tend to underesti-
mate higher GFRs [12]. Meanwhile, the CKD-EPI (CKD
Epidemiology Collaboration) equation has been evaluated
in several populations and become the most accurate
GFR estimating equation [13–15]. Recently, the CKD-
EPI equation has been recommended as the first-choice
method to assess renal function by the 2016 European
AIDS Clinical Society (EACS) Guidelines [16].
This study aimed to analyze eGFR in a large cohort of
patients with HIV infection followed-up in a single center
and to evaluate the renal function estimation obtained by
the CKD-EPI versus the MDRD equation, also stratifying
patients according to different degrees of chronic kidney
disease.
Methods
This was an observational, cross-sectional, retrospective,
single center study. The study project was reviewed and
approved by the Institutional Review Board (CEIC
Hospital Clinic i Provincial, Barcelona, Spain, IRB#
2014/1080). Eligible patients were all adult HIV-1-
infected patients (>18 years old) with at least one routine
visit during the calendar year of 2014. Patients were
excluded if they had not had at least two measurements
of serum creatinine during the year 2014 and/or if they
had had a diagnosis of end stage renal disease, dialysis
and/or transplantation before the diagnosis of HIV
infection. Patients were considered as having hyperten-
sion, diabetes and/or dyslipidemia if they were receiving
specific treatment for these conditions.
All available serum creatinine values were obtained
from the hospital electronic patient record system
and were converted into eGFR, using age, gender and
the CKD-EPI and MDRD equations. We did not con-
sider the African-American coefficient factor as ap-
plicable to black patients from Africa, Europe and the
Antilles [17], because this information is not available
in the electronic medical records, although the preva-
lence of black patients in our institution, regardless
their HIV-status, is very low (<3%).
Impaired renal function (eGFR <90 mL/min/1.73 m2)
was confirmed with a second measurement at least
3 months apart from the first “baseline” creatinine. We
used clinical guidelines from the US National Kidney
Foundation’s Kidney Disease Outcome Quality Initiative
(K/DOQI) to grade renal impairment [18]. In this study,
eGFR below 60 mL/min/1.73 m2 was used as the cutoff
point for chronic kidney disease (CKD).
Statistical analyses were performed using the Predict-
ive Analytics Software statistics for Windows, v21.0
(SPSS Inc, Chicago, IL). Normal distribution of data was
assessed by the Kolmogorov-Smirnov test and data were
presented as mean (±SD) or as median (interquartile
range) where appropriate. Categorical variables were
presented as absolute frequency and percentage. When
analyzing baseline eGFR, the Mann-Whitney U test was
used to make comparisons.
Agreement between the CKD-EPI and MDRD equa-
tions was assessed using the general linear model. The
Bland and Altman method was used to estimate the glo-
bal bias throughout the mean difference between GFR
values and plot the differences against their means. The
Kappa index was used to analyze the level of agreement
between the NKF stage classifications obtained using
CKD-EPI and MDRD. Statistical significance was consid-
ered if the p-value <0.05.
Results
Of the 4622 eligible patients with follow-up in 2014,
4503 were included for analysis. Excluded patients (six
patients were diagnosed with end stage renal disease
before HIV-infection, and the remaining 113 patients
had no laboratory data in 2014) were less likely to be
smokers, had a shorter duration of HIV infection (7.7 vs.
12.3 years), were less likely to be on antiretroviral treat-
ment (91.5% vs. 97.3%), and had higher nadir CD4
counts and lower viral loads (data not shown).
Demography
Demographic characteristics are depicted in Table 1.
Median age was 45 years [interquartile range (IQR)
37–52], median body mass index was 22.9 kg/m2
(IQR 21.2–24.9), and median “baseline” creatinine was
0.93 mg/dL (IQR 0.82–1.05). Ethnicity was available
for 2/3 of the patients; 98% of them were non-black.
History of hypertension, diabetes, and dyslipidemia
was noted in 14, 5, and 13% of patients, respectively,
and 5% of the patients had prior cardiovascular dis-
eases. Median duration of HIV infection was 11 years
(IQR 5–19), 20% met the clinical definition for AIDS;
4365 patients (97%) were receiving combined ARV,
and 89% had the status of virological suppression
under treatment.
GFR evaluation
Overall baseline median eGFR was 95.2 mL/min/1.73 m2
and 90.4 mL/min/1.73 m2 by the CKD-EPI and MDRD
creatinine equations, respectively (p < 0.001).
In the absence of a gold standard method for estimat-
ing GFR, we considered two models of comparison:
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using CKD-EPI as reference and then using MDRD as
reference measure. When considering only patients with
eGFR ≥60 mL/min/1.73 m2 and CKD-EPI estimation as
reference, baseline mean eGFR was 95.12 mL/min/
1.73 m2 and 92.99 mL/min/1.73 m2 by CKD-EPI and
MDRD equations, respectively (p < 0.001). When using
the MDRD estimation as reference, baseline mean eGFR
was 95.21 mL/min/1.73 m2 and 93.11 mL/min/1.73 m2
by CKD-EPI and MDRD creatinine equations, respectively
(p < 0.001). When considering only patients with eGFR
<60 mL/min/1.73 m2 and CKD-EPI estimation as refer-
ence, baseline mean eGFR was 48.08 mL/min/1.73 m2 and
48.60 mL/min/1.73 m2 by CKD-EPI and MDRD equa-
tions, respectively (p = 0.999). When using MDRD estima-
tion as reference, baseline mean eGFR was 48.79 mL/min/
1.73 m2 and 48.83 mL/min/1.73 m2 by CKD-EPI and
MDRD equations, respectively (p = 0.999).
Using the two consecutive measures of serum creatin-
ine, the classification of patients for stages of CKD is
presented in Table 2. When using the CKD-EPI formula
as reference, 1091 (24.2%) patients presented mild re-
duced GFR, 118 (2.6%) patients had stage 3 CKD, and 5
(0.11%) patients presented stage 4 CKD. When using the
MDRD formula as reference, 1396 (31%) patients pre-
sented mild reduced GFR, 116 (2.6%) patients had stage
3 CKD, and 2 (0.04%) patients presented stage 4 CKD.
There were 19 patients under renal substitutive therapy
at baseline (11 on dialysis and 8 kidney transplant recipi-
ents), classified as stage 5 CKD. However, the MDRD
equation has not been validated for normal GFR, and is
it not possible to discriminate between GFR > 90 mL/
min/1.73 m2 and between 60 and 89 mL/min/1.73 m2;
they should be reported as “≥60 mL/min/1.73 m2”. On
the contrary, CKD-EPI can report these two stages
separately.
CKD-EPI versus MDRD equations
A substantial agreement was found between the MDRD
and CKD-EPI creatinine formulae. When evaluating the
absolute measures of eGRF, there was a similar distribu-
tion both in the baseline measure (p = 0.548) and in the
second measure (p = 0.259).
Figure 1 shows a Bland-Altman plot of the agreement
between the MDRD and CKD-EPI equations for the
baseline measure and second measure of creatinine.
Overall, the mean (SD) difference between the estimates
from the two formulae was 2.003, with limits of agree-
ment of 16.753 to -12.753 for the baseline measure, and
0.8232, with limits of agreement of 17.636 to -15.9896,
for the second measure of creatinine.
Of the 4503 measurements, 4109 (91.2%) agreed, that is,
they were classified as normal, mildly decreased, moder-
ately decreased (stage 3), severely decreased (stage 4) or
end-stage renal insufficiency (stage 5) with both formulae,
with a kappa index of 0.803. However, 7.3% of patients
were classified as having “mild renal impairment” with the
MDRD equation but as having “normal renal function”
with the CKD-EPI equation.
Discussion
In this large sample of HIV-infected patients, there was
a good correlation between the CKD-EPI and MDRD
equations. The CKD-EPI equation gave somewhat higher
eGFR estimates than the MDRD formula (95.2 mL/min/
Table 1 Main demographic characteristics of 4503 patients with
HIV infection included in the study
Variable Estimates n Missing
information
Median age, years (IQR) 45 (37–52) 4503 0
Female sex, n (%) 864 (19) 4503 0
Black race, n (%) 58 (2) 2879 1624
Body mass index, kg/m2 (IQR) 22.9 (21.2–24.9) 1394 3109
Current smoker, n (%) 2110 (51) 4154 349
Hypertension, n (%) 619 (14) 4503 0
Diabetes mellitus, n (%) 225 (5) 4503 0
Dyslipidemia, n (%) 596 (13) 4503 0
Cardiovascular disease, n (%) 202 (5) 4503 0
Hepatitis B coinfection, n (%) 149 (3) 4485 18
Hepatitis C coinfection, n (%) 1006 (22) 4495 8
Mode of HIV acquisition, n (%)a 4503 0
Homo/bisexual 2650 (62)
Heterosexual 1176 (28)
Injection drug use 641 (15)
Other/Unknown route 290 (6)
Duration of HIV infection,
years (IQR)
11.3 (5.1–19) 4478 25
Prior AIDS (yes), n (%) 900 (20) 4503 0
Current ART regimen 4503 0
No treatment 138 (3)
NNRTI-based 2381 (53)
PI-based 144 (3)
Boosted PI-based 1315 (29)
Integrase inhibitors-based 493 (11)
Others 32 (1)
Nadir CD4 cell count (IQR) 249 (129–369) 4484 19
Current CD4 cell count (IQR) 628 (450–830) 4501 2
Current HIV infection status 4503 0
Suppression on Treatment 4031 (90)
No suppression (viral load >
50 copies)
471 (10)
IQR, interquartile range; HIV, human immunodeficiency virus; AIDS, acquired
immunodeficiency syndrome; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor
aPatients can present more than one HIV transmission route
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1.73 m2 and 90.4 mL/min/1.73 m2 by CKD-EPI and
MDRD creatinine equations, respectively; p < 0.001),
resulting in smaller but non-significant numbers of
patients with eGFR <90 mL/min/1.73 m2 (27.4% vs.
34%). Although the clinical relevance of the difference
found should be interpreted with caution, our data are
consistent with observations in the general [19, 20] and
HIV-infected populations [21], suggesting that MDRD
may overestimate the severity of renal impairment. Stud-
ies in the general population comparing CKD-EPI and
MDRD against isotopic GFR observed less bias, im-
proved precision and greater accuracy with CKD-EPI
[22], although others have found lesser mean bias with
MDRD [23].
In this analysis, at least a quarter of patients were
diagnosed with mild reduced GFR disease (eGFR 60–
89 mL/min/1.73 m2). This is important in detecting
subclinical renal disease and identifying those patients
with a higher cardiovascular risk or at risk of developing
declining renal function. In practical terms, detecting
Table 2 Grades of renal impairment according the National Kidney Foundation guidelines. Comparison of classifications provided
using CKD-EPI and MDRD equationsa. Absolute frequencies (A) and percentages (B) of the studied population
aShaded cells indicate agreement between CKD-EPI and MDRD-derived eGFR estimations
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minor changes in eGFR allows the early adoption of
lifestyle modification and medication therapies, as ap-
propriate, to control hypertension, dyslipidemia and
hyperglycemia. In addition, nephrotoxic medications
should be avoided, and medication doses (particularly
when prescribing ARV) must be adjusted for renal func-
tion. For example, Stribild® (combination of emtricitabine,
tenofovir disoproxil fumarate, cobicistat and elvitegravir
for a complete 1-pill, once-a-day HIV-1 treatment) pre-
scription information contraindicates the use of this drug
in patients with eGFR below 70 mL/min/1.73 m2 [24].
The MDRD equation misdiagnosed patients with apparent
‘normal’ renal function (over 60 mL/min/1.73 m2).
Chronic kidney disease stages III-V (eGFR <60 mL/
min/1.73 m2) were found in 3% of HIV-infected patients
with both equations, a prevalence similar to the Euro-
SIDA study and the French [25, 26] cohorts. However,
this prevalence was lower than that found in a recent
American analysis, in which 7.5% of HIV-infected
patients had CKD [27], and even lower than a Nigerian
analysis [28] that showed 52.6% of patients with GFR
<60 mL/min. Possible explanations are the higher
Fig. 1 Bland Altman plot of agreement between MDRD and CKD-EPI equations for baseline measure (a) and second measure of creatinine (b)
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proportions of blacks and hypertensive patients on
American and Nigerian cohorts, the duration of
untreated HIV infection, the length of exposure to
nephrotoxic antiretrovirals, as well as lifestyle-related
variables and socioeconomic factors reported to impact
health care coverage [29].
This study has some limitations: first, its retrospect-
ive nature; second, the absence of a direct measure of
glomerular filtration rate for comparison; third, the
unavailability of urine protein/creatinine ratios; and,
finally the absence of an outcome measure for those
patients with a reduced eGFR, which fell outside the
scope of this study.
In summary, the evaluation of renal function is essential
for the clinical management of patients with HIV-
infection. In line with observations in the general popula-
tion, this study suggests that the MDRD equation may
underestimate renal function in subjects with GFRs over
60 mL/min/1.73 m2. The main contribution of this report
was that the CKD-EPI equation identified 24% of patients
with mild reduced eGFR, not identified using the MDRD
equation. This finding has strong implications for clinical
practice, as it provides a framework for identifying
patients at risk of poorer outcomes (overt chronic kidney
disease, cardiovascular disease and mortality) and allows
better clinical management, especially in terms of the dose
adjustment of antiretroviral drugs.
Conclusion
In conclusion, the CKD-EPI equation must be considered
as the first-choice method to evaluate renal function in
patients with HIV-infection.
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